Article

You have full text access to this OnlineOpen article

Mutations of key hydrophobic surface residues of 11β-hydroxysteroid dehydrogenase type 1 increase solubility and monodispersity in a bacterial expression system

  1. Alexander J. Lawson1,
  2. Elizabeth A. Walker2,
  3. Scott A. White1,
  4. Timothy R. Dafforn1,
  5. Paul M. Stewart2,
  6. Jonathan P. Ride1,*

Article first published online: 29 APR 2009

DOI: 10.1002/pro.150

Issue

Protein Science

Protein Science

Volume 18, Issue 7, pages 1552–1563, July 2009

Additional Information

How to Cite

Lawson, A. J., Walker, E. A., White, S. A., Dafforn, T. R., Stewart, P. M. and Ride, J. P. (2009), Mutations of key hydrophobic surface residues of 11β-hydroxysteroid dehydrogenase type 1 increase solubility and monodispersity in a bacterial expression system. Protein Science, 18: 1552–1563. doi: 10.1002/pro.150

Author Information

  1. 1

    School of Biosciences, University of Birmingham, Birmingham B15 2TT, United Kingdom

  2. 2

    School of Clinical and Experimental Medicine, University of Birmingham, Birmingham B15 2TT, United Kingdom

*School of Biosciences, University of Birmingham, PO Box 363, Birmingham B15 2TT, UK

Publication History

  1. Issue published online: 23 JUN 2009
  2. Article first published online: 29 APR 2009
  3. Accepted manuscript online: 29 APR 2009 12:00AM EST
  4. Manuscript Accepted: 9 APR 2009
  5. Manuscript Revised: 6 APR 2009
  6. Manuscript Received: 11 FEB 2009

Funded by

  • The Wellcome Trust. Grant Number: 082809/Z/07/Z

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (747K)

References

  • 1
    Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM ( 2004) 11 β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25: 831–866.
  • 2
    Krozowski Z, Stuchbery S, White P, Monder C, Funder JW ( 1990) Characterization of 11 β-hydroxysteroid dehydrogenase gene expression: identification of multiple unique forms of messenger ribonucleic acid in the rat kidney. Endocrinology 127: 3009–3013.
  • 3
    Draper N, Stewart PM ( 2005) 11 β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 186: 251–271.
  • 4
    Tomlinson JW, Stewart PM ( 2005) Mechanisms of disease: selective inhibition of 11 β-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metab 1: 92–99.
  • 5
    Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS ( 2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294: 2166–2170.
  • 6
    Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS ( 2003) Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112: 83–90.
  • 7
    Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ ( 2004) Metabolic syndrome without obesity: hepatic overexpression of 11 β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101: 7088–7093.
  • 8
    Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ ( 1997) 11 β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94: 14924–14929.
  • 9
    Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR ( 2001) Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11 β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276: 41293–41300.
  • 10
    Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Björkstrand E, Abrahmsen LB ( 2003) Selective inhibition of 11 β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144: 4755–4762.
  • 11
    Bhat BG, Hosea N, Fanjul A, Herrera J, Chapman J, Thalacker F, Stewart PM, Rejto P ( 2007) Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with PF-915275, an inhibitor of 11{β}HSD1, in cynomolgus monkeys. J Pharmacol Exp Ther 5: 5.
  • 12
    Ozols J ( 1995) Lumenal orientation and post-translational modifications of the liver microsomal 11 β-hydroxysteroid dehydrogenase. J Biol Chem 270: 10360.
  • 13
    Maser E, Volker B, Friebertshauser J ( 2002) 11 β-Hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 41: 2459– 2465.
  • 14
    Hosfield DJ, Wu Y, Skene RJ, Hilgers M, Jennings A, Snell GP, Aertgeerts K ( 2005) Conformational flexibility in crystal structures of human 11 β-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation. J Biol Chem 280: 4639–4648.
  • 15
    Mziaut H, Korza G, Hand AR, Gerard C, Ozols J ( 1999) Targeting proteins to the lumen of endoplasmic reticulum using N-terminal domains of 11 β-hydroxysteroid dehydrogenase and the 50-kDa esterase. J Biol Chem 274: 14122–14129.
  • 16
    Odermatt A, Arnold P, Stauffer A, Frey BM, Frey FJ ( 1999) The N-terminal anchor sequences of 11 β-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 274: 28762–28770.
  • 17
    Walker EA, Clark AM, Hewison M, Ride JP, Stewart PM ( 2001) Functional expression, characterization, and purification of the catalytic domain of human 11-β-hydroxysteroid dehydrogenase type 1. J Biol Chem 276: 21343– 21350.
  • 18
    Filling C, Nordling E, Benach J, Berndt KD, Ladenstein R, Jornvall H, Oppermann U ( 2001) Structural role of conserved Asn179 in the short-chain dehydrogenase/reductase scaffold. Biochem Biophys Res Commun 289: 712–717.
  • 19
    Blum A, Martin HJ, Maser E ( 2000) Human 11 β-hydroxysteroid dehydrogenase type 1 is enzymatically active in its nonglycosylated form. Biochem Biophys Res Commun 276: 428–434.
  • 20
    Filling C, Berndt KD, Benach J, Knapp S, Prozorovski T, Nordling E, Ladenstein R, Jornvall H, Oppermann U ( 2002) Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. J Biol Chem 277: 25677–25684.
  • 21
    Oppermann UC, Filling C, Jornvall H ( 2001) Forms and functions of human SDR enzymes. Chem Biol Interact 130-132: 699–705.
  • 22
    Wimley WC, White SH ( 1996) Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat Struct Biol 3: 842–848.
  • 23
    Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE ( 2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25: 1605–1612.
  • 24
    Ogg D, Elleby B, Norstrom C, Stefansson K, Abrahmsen L, Oppermann U, Svensson S ( 2005) The crystal structure of guinea pig 11 β-hydroxysteroid dehydrogenase type 1 provides a model for enzyme-lipid bilayer interactions. J Biol Chem 280: 3789–3794.
  • 25
    Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE ( 2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5: 121–131.
  • 26
    Pernecky SJ, Larson JR, Philpot RM, Coon MJ ( 1993) Expression of truncated forms of liver microsomal P450 cytochromes 2B4 and 2E1 in Escherichia coli: influence of NH2-terminal region on localization in cytosol and membranes. Proc Natl Acad Sci USA 90: 2651–2655.
  • 27
    Schuck P ( 2000) Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J 78: 1606–1619.
  • 28
    Zhang J, Osslund TD, Plant MH, Clogston CL, Nybo RE, Xiong F, Delaney JM, Jordan SR ( 2005) Crystal structure of murine 11 β-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes. Biochemistry 44: 6948–6957.
  • 29
    DeLano WL ( 2002) The PyMOL molecular graphics System. Palo Alto, CA: DeLano Scientific.
  • 30
    Krissinel E, Henrick K ( 2007) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774–797.
  • 31
    Sim J, Sim TS ( 1999) Amino acid substitutions affecting protein solubility: high level expression of Streptomyces clavuligerus isopenicillin N synthase in Escherichia coli. J Mol Catal B 6: 133–143.
  • 32
    Daujotyte D, Vilkaitis G, Manelyte L, Skalicky J, Szyperski T, Klimasauskas S ( 2003) Solubility engineering of the HhaI methyltransferase. Protein Eng 16: 295–301.
  • 33
    Mosavi LK, Peng ZY ( 2003) Structure-based substitutions for increased solubility of a designed protein. Protein Eng 16: 739–745.
  • 34
    Dale GE, Broger C, Langen H, Darcy A, Stuber D ( 1994) Improving protein solubility through rationally designed amino-acid replacements—solubilization of the trimethoprim-resistant type S1 dihydrofolate-reductase. Protein Eng 7: 933–939.
  • 35
    Nieba L, Honegger A, Krebber C, Pluckthun A ( 1997) Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng 10: 435–444.
  • 36
    Elleby B, Svensson S, Wu X, Stefansson K, Nilsson J, Hallen D, Oppermann U, Abrahmsen L ( 2004) High-level production and optimization of monodispersity of 11 β-hydroxysteroid dehydrogenase type 1. Biochim Biophys Acta 1700: 199–207.
  • 37
    Arampatzis S, Kadereit B, Schuster D, Balazs Z, Schweizer RA, Frey FJ, Langer T, Odermatt A ( 2005) Comparative enzymology of 11 β-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 35: 89–101.
  • 38
    Castro A, Zhu JX, Alton GR, Rejto P, Ermolieff J ( 2007) Assay optimization and kinetic profile of the human and the rabbit isoforms of 11 β-HSD1. Biochem Biophys Res Commun 357: 561–566.
  • 39
    Shafqat N, Elleby B, Svensson S, Shafqat J, Jornvall H, Abrahmsen L, Oppermann U ( 2003) Comparative enzymology of 11 β -hydroxysteroid dehydrogenase type 1 from glucocorticoid resistant (Guinea pig) versus sensitive (human) species. J Biol Chem 278: 2030–2035.
  • 40
    Walker A ( 2000) In vivo functions and applications of molecular chaperones. PhD Thesis, University of Birmingham.
  • 41
    Kabsch W ( 1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 26: 795–800.
  • 42
    Perrakis A, Morris R, Lamzin VS ( 1999) Automated protein model building combined with iterative structure refinement. Nat Struct Biol 6: 458–463.
  • 43
    Afonine PV, Grosse-Kunstleve RW, Adams PD ( 2005) The phenix refinement framework. CCP4 Newsletter 42 (Contribution 8).
View Full Article (HTML) Get PDF (747K)